Newron Pharmaceuticals SpA (NWRN) — Capital Reinvestment Ratio
Latest as of June 2025:
0.00x
Newron Pharmaceuticals SpA (NWRN) has a Capital Reinvestment Ratio of 0.00x as of June 2025, meaning it reinvests 0% of its operating cash flow (CHF33.35 Million) in capital expenditures (CHF31.00K). See cash generation quality of Newron Pharmaceuticals SpA to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
CHF33.35 Million
CHF
Capital Expenditures
CHF31.00K
CHF
Data as of
Jun 2025
Most recent filing
Newron Pharmaceuticals SpA Capital Reinvestment Ratio (2012–2025)
This chart tracks Newron Pharmaceuticals SpA's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Newron Pharmaceuticals SpA (2012–2025)
Year-by-year Capital Reinvestment Ratio for Newron Pharmaceuticals SpA from 2012 to 2025. For live market cap and broader valuation context, see market cap of Newron Pharmaceuticals SpA.
| Year | Reinvestment Ratio | Operating CF (CHF) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | CHF32.56 Million | CHF47.30K | ▼ -23.1% |
| 2012 | 0.00x | CHF5.83 Million | CHF11.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow